Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 321

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 321
---
 table reconciles
the undiscounted future minimum lease payments under the non-cancelable operating lease with terms of more than to the total
operating lease liabilities recognized on the Company’s balance sheet as of March 31, 2025:

Maturity of the Company’s
lease liabilities as of March 31, 2025 is as follows:

| 2025 (remainder of year) |     | $ |   744,992 |   |
| 2026                     |     |   |   726,394 |   |
| Total lease payments     |     |   | 1,471,386 |   |
| Less: imputed interest   |     |   |  (104,801 | ) |
| Total lease liabilities  |     | $ | 1,366,585 |   |

NOTE 8 – STOCKHOLDERS’ DEFICIT Successor Series A Convertible Preferred Stock The Company designated 12,580shares of its authorized preferred stock as the Series A Preferred Stock and the rights, preferences and privileges of the Series A Preferred Stock are summarized below. Each share of Series A Preferred Stock has a stated value of $ 1,000per share and, when issued, the Series A Preferred Stock was fully paid and non-assessable. The Series A Preferred Stock, ranks senior to all other Company capital stock unless required holder votes are obtained to create a class of stock senior to Series A Preferred Stock. The requisite holders of Series A Preferred Stock consented to the issuance of the Series C Preferred Stock described below, which ranks senior to the Series A Preferred Stock and Series B Preferred Stock. Dividend and Participation Rights:The holders of Series A Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on shares of Common Stock, when and if actually paid. Series A Preferred Stockholders will be entitled to participate pro rata in any purchase rights extended to holders of Common Stock on an as-converted basis. Conversion: Each holder of Series A Preferred Stock may convert at any time, all, or any part, of the outstanding Series A Preferred Stock into shares of the Common Stock at the initial “Conversion Price” of $ 20,000, which is subject to customary adjustments for stock splits. The Company’s Board of Directors has the right, at any time, with the written consent of the Required Holders (as defined in the Certificate of Designation of Preferences, Rights and Limitations of the Series A